0001104659-24-023870.txt : 20240214 0001104659-24-023870.hdr.sgml : 20240214 20240214165049 ACCESSION NUMBER: 0001104659-24-023870 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 EFFECTIVENESS DATE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-505332 FILM NUMBER: 24639779 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 D 1 primary_doc.xml X0708 D LIVE 0001017491 SEELOS THERAPEUTICS, INC. 300 PARK AVENUE 2ND FLOOR NEW YORK NY NEW YORK 10022 (646) 293-2100 NEVADA None APRICUS BIOSCIENCES, INC. NEXMED INC Corporation true Raj Mehra c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Director Brian Lian c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Richard W. Pascoe c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Daniel J. O'Connor c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Margaret Dalesandro c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Michael Golembiewski c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Biotechnology No Revenues 06b false 2024-01-30 false true true false 0 A.G.P./Alliance Global Partners 8361 None None 590 MADISON AVENUE, 28TH FOOR NEW YORK NY NEW YORK 10022 NJ NEW JERSEY NY NEW YORK false 3574468 0 3574468 Represents the aggregate exercise price of warrants to purchase 3,404,256 shares of the Company's common stock, which were issued in connection with an offering of 3,404,256 shares of the Company's common stock issued in a registered direct offering. false 3 280000 65000 $280.000.00 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $65,000 is for the reimbursement of expenses incurred by the placement agent. 0 false SEELOS THERAPEUTICS, INC. /s/ Michael Golembiewski Michael Golembiewski Chief Financial Officer 2024-02-14